Pillar Biosciences Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Natick, MA USA
Total Funding:$18M
Industry:Biotech
Founded:2014
Lead Investor(s):ORI Healthcare Fund L.P
Claim your profile

Estimated Revenue & Financials

  • Pillar Biosciences's estimated annual revenue is currently $7.3M per year.
  • Pillar Biosciences received $18.0M in venture funding in May 2016.
  • Pillar Biosciences's estimated revenue per employee is $155,000
  • Pillar Biosciences's total funding is $18M.

Employee Data

  • Pillar Biosciences has 47 Employees.
  • Pillar Biosciences grew their employee count by 2% last year.
  • Pillar Biosciences currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ultivue
$8.7M56-12%N/A
Ohana Bioscienc...
$8.7M5660%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

Pillar Biosciences aims to "Make Precision Medicine Accessible" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today's high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

47

Number of Employees

$7.3M

Revenue (est)

1

Current Jobs

2%

Employee Growth %

$18M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Peter ChryssanthacopoulosSr. Manager, Quality Assurance and Regulatory Compliance. ISO Mgmt Representative. Email Available
Geoffrey RichmanSr. Product Manager
Jerry RiehlMarket Development Manager
Yue KePrincipal Data Scientist / Director
Jamie LimSr Project Manager
William WrightDirector of Sales
Sun LimMarket Development Manager
Gang SongPresident/CEO
Arie HenkinSenior Manager, QA/RA and Operations
Dina HainesQuality Control Manager

Pillar Biosciences News

09/03/2019 - Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel

BOSTON, May 30, 2019 /PRNewswire/ -- Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today ...

01/10/2019 - Pillar Biosciences enters strategic partnership with China ...

SAN FRANCISCO, Jan. 10, 2019 /PRNewswire/ -- Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA, USA ...

09/03/2019 - DxPx partners with MyBioGate for China

... Pillar Biosciences, Medicover, and Hightech Gründerfund, Europe's leading startup investor, McDermott Will & Emery as well as Aescuvest.

Pillar Biosciences Funding

DateAmountRoundLead InvestorsReference
2016-05-12$18.0MUndisclosedORI Healthcare Fund L.PArticle